Risk of Stroke After Exacerbation of Ischemic Heart Disease: Data of 3-Years Follow-up

Purpose: to analyze possible associations of clinical and genetic factors with development of ischemic stroke after exacerbation of ischemic heart disease (IHD). Materials and methods: RAe Russian multicenter study aimed at assessment of risk of unfavorable outcomes after exacerbation of IHD "Exacerbation of IHD: logical probabilistic ways to course prognostication for optimization of treatment” (meaning of Cyrillic acronym - oracle) was conducted in 16 centers of 7 cities in Russia. We included into the study 1 208 patients with unstable angina and ST-elevation or non-ST-elevation myocardial infarction (MI). Data on outcomes were known for 1 193 patients, 15 patients were lost for follow-up. Results. Mean duration offollow-up was 644±14.45 (4-1 995) days. Shortest, longest, and mean time before development of stroke was 22, 1433 and 389±56.6 days after inclusion. Patients with strokes were older, more often had history of IHD prior to index hospitalization, arterial blood pressure level compatible with stage 3 arterial hypertension, less often were smokers, and more often had MI recurrences or repetitive episodes of severe ischemia during the index hospitalization. Patients also more often had documented atrial fibrillation during hospitalization, and lower level of glomerular filtration rate. Of studied genetic markers carriage of A allele of polymorphic marker G (-1082) A of interleukin-10 gene was significantly associated with risk of stroke development. Using linear regression analysis, we constructed a model of estimation of the stroke development risk. Comparison of diagnostic value of different scales for stroke risk assessment showed that area under the curve was 0.656, 0.686, and 0.756 for the GRACE, CHA₂DS₂-VASc, and ORACLE scores, respectively.

острый коронарный синдром, инсульт, ген интерлейкина-10, acute coronary syndrome, stroke, interleukin-10 gene

1. Eckel R. H., Jakicic J. M., Ard J. D. et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63 (25):2960-2984. DOI: 10.1016/j. jacc. 2013.11.003.

2. Hankey G.J. Ue ABCD, California, and unified ABCD2 risk scores predicted stroke within 2, 7, and 90 days after TIA. ACP J Club 2007;146 (3):79.

3. Weimar C., Diener H. C., Alberts M. J. et al. REduction of Atherothrombosis for Continued Health Registry Investigators. The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the REduction of Atherothrombosis for Continued Health (REACH) registry. Stroke 2009;40 (2):350-354.

4. Lip G. Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrilla tion using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-272.

5. Затейщиков Д. А., Волкова Э. Г., Гузь И. О. и др. Лечение больных, перенесших острый коронарный синдром, по данным Российского многоцентрового проспективного наблюдательного исследования. Фарматека 2009;12:109-113

6. Park K. L., Budaj A., Goldberg R.J. et al. Grace Investigators. Risk-prediction model for ischemic stroke in patients hospitalized with an acute coronary syndrome (from the global registry of acute coronary events [G^ACE]). Am J. Cardiol 2012;110 (5):628-635. DOI: 10.1016/j.amjcard. 2012.04.040.

7. Al Suwaidi J., Habib A. K., Asaad N. et al. Immediate and one-year outcome of patients presenting with acute coronary syndrome complicated by stroke: findings from the 2nd Gulf Registry of Acute Coronary Events (Gulf ^ACE-2). BMC Cardiovasc Disord 2012;12:64. DOI: 10.1186/1471-2261-12-64.

8. Segev A., Strauss B. H., Tan M. et al. Canadian Acute Coronary Syndrome Registries Investigators. Risk factors and outcome of in-hospital ischemic stroke in patients with non-ST elevation acute coronary syndromes. Int J. Cardiol 2008; 129 (2):233-237.

9. Cronin L., Mehta S. R., Zhao F. et al. Stroke in relation to cardiac procedures in patients with non-ST-elevation acute coronary syndrome: a study involving >18 000 patients. Circulation 2001;104 (3):269-274.

10. Budaj A., Flasinska K., Gore J. M. et al. G^ACE Investigators. Magnitude of and risk factors for in-hospital and postdischarge stroke in patients with acute coronary syndromes: findings from a Global Registry of Acute Coronary Events. Circulation 2005;111 (24):3242-3247.

11. Alvarez-Alvarez B., Raposeiras-Roubin S., Abu-Assi E. et al. Is 6-month GRACE risk score a useful tool to predict stroke after an acute coronary syndrome? Open Heart 2014;1 (1):e000123. DOI: 10.1136/openhrt-2014-000123.

12. Mitchell L. B., Southern D. A., Galbraith D. et al. APPROACH investigators. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA^DSj-VASc scores. Heart 2014;100 (19):1524-1530. DOI: 10.1136/heartjnl-2013-305303.

13. Stein C. M., Zalwango S., Chiunda A. B. et al. Linkage and association analysis of candidate genes for TB and TNFalpha cytokine expression: evidence for association with IFNGR1, IL-10, and TNF receptor 1 genes. Hum Genet 2007;121 (6):663-673.

14. Lard L. R., van Gaalen F. A., Schonkeren J.J. et al. Association of the -2849 interleukin-10 promoter polymorphism with auto antibody production and joint destruction in rheumatoid arthritis. Arthritis Rheum 2003;48 (7):1841-1848.

15. Li W. Z., Gao C. Y., He W. L., Zhang H. M. Association of the interleukin-10 gene -1082A/G. genetic polymorphism with risk of ischemic stroke in a Chinese population. Genet Mol Res 2016;15(1). DOI: 10.4238/gmr. 15017541.

16. Jiang X. H., Lin K. X., Zhang Y. X. et al. Correlating interleukin-10 promoter gene polymorphisms with human cerebral infarction onset. Neural Regen Res 2015;10 (11 ): 1809-1813. DOI: 10.4103/1673-5374.170308.

17. Kumar P., Kumar A., Sagar R. et al. Association between Interleukin-10-1082G/A Gene Polymorphism and Risk of Stroke in the North Indian Population: A Case-Control Study. J. Stroke Cerebrovasc Dis 2016;25 (2):461-468. DOI: 10.1016/j.jstrokecerebrovasdis. 2015.10.020.

18. Trompet S., Pons D., Craen A. J. et al. Genetic variation in the interleukin-10 gene promoter and risk of coronary and cerebrovascular events: the PROSPER study. Ann N. Y. Acad Sci 2007;1100:189-198.

19. Xie G., Myint P. K., Zaman M.J. et al. Relationship of serum interleukin-10 and its genetic variations with ischemic stroke in a Chinese general population. PLoS One 2013;8 (9):e74126. DOI: 10.1371/journal. pone. 0074126.

20. Liang Q.J., Jiang M., Wang X. H. et al. Fre-existing interleukin-10 in cerebral arteries attenuates subsequent brain injury caused by ischemia/reperfusion. IUBMB Life 2015;67 (9):710-719. DOI: 10.1002/iub. 1429.

21. Liesz A., Bauer A., Hoheisel J. D., Veltkamp R. Intracerebral interleukin-10 injection modulates post-ischemic neuroinflammation: an experimental microarray study. Neurosci Lett 2014;579:18-23. DOI: 10.1016/j. neulet. 2014.07.003.

22. Chao L., Lei H., Fei J. A meta-analysis of interleukin-10-1082 promoter genetic polymorphism associated with atherosclerotic risk. Neurol India 2014;62 (2): 130-136. DOI: 10.4103/0028-3886.132323.

23. Jiang X. H., Lin K. X., Zhang Y. X. et al. Correlating interleukin-10 promoter gene polymorphisms with human cerebral infarction onset. Neural Regen Res 2015;10 (11 ): 1809-1813. DOI: 10.4103/1673-5374.170308.

24. Rees L. E., Wood N. A., Gillespie K. M. et al. ^e interleukin-10-1082 G/A polymorphism: allele frequency in different populations and functional significance. Cell Mol Life Sci 2002;59 (3):560-569.

25. Crawley E., Kay R., Sillbourne J. et al. Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999;42:1101-1108.